Evidence of the Biomarkers from the Sub-analysis Data of Clinical Trials and Registries

Abstract

Biomarkers are substances derived from organs, which can be measured and evaluated as indicators of normal biology, pathogenic process or pharmacological response to a therapeutic intervention. Their measurements is not subject to inter-observer variability. An ideal biochemical marker should be a prognostic indicator, assist in the early diagnosis of heart failure (HF), reliably reflect the therapeutic response, and help grading the risk associated with each stage of HF. While several biochemical markers have been studied for their prognostic value in the setting of chronic and acute HF, their clinical applications have not been systematically discussed. Moreover, change of ideal biomarkers should correlate the change of cardiovascular events. The relationship between cardiac remodeling and these biomarkers also should be elucidated. Finally, an ideal biochemical marker should be applicable to patients at the risk stage of HF. Biomarkers, such as CRP, BNP, collagen marker and high sensitive cardiac troponin has been reported as a prognostic marker of cardiovascular events in general population.In this symposium, we review biomarkers from the sub-analysis data of clinical trials and registries from, risk stage to overt HF. Biomarkers are substances derived from organs, which can be measured and evaluated as indicators of normal biology, pathogenic process or pharmacological response to a therapeutic intervention. Their measurements is not subject to inter-observer variability. An ideal biochemical marker should be a prognostic indicator, assist in the early diagnosis of heart failure (HF), reliably reflect the therapeutic response, and help grading the risk associated with each stage of HF. While several biochemical markers have been studied for their prognostic value in the setting of chronic and acute HF, their clinical applications have not been systematically discussed. Moreover, change of ideal biomarkers should correlate the change of cardiovascular events. The relationship between cardiac remodeling and these biomarkers also should be elucidated. Finally, an ideal biochemical marker should be applicable to patients at the risk stage of HF. Biomarkers, such as CRP, BNP, collagen marker and high sensitive cardiac troponin has been reported as a prognostic marker of cardiovascular events in general population. In this symposium, we review biomarkers from the sub-analysis data of clinical trials and registries from, risk stage to overt HF.